

DAFTAR PUSTAKA

- Abdul-Ghani, M., DeFronzo, R. Pathogenesis of Insulin Resistance in Skeletal Muscle. *J. Biomed. Biotechnol*, 2010, 2010: 1–19.
- ADA, Standards of Medical Care in Diabetes--2012. *Diabetes Care*, 2012, 35 (Suppl 1): S11–S63.
- AHA, 2016. *What is Cardiovascular Disease?*, (Online), (http://www.heart.org/HEARTORG/Caregiver/Resources/WhatisCardiovascularDisease/What-is-Cardiovascular-Disease_UCM_301852_Article.jsp#.WCx8x8knKFs, diakses 28 Oktober 2016)
- Alkaitis, M.S., Crabtree, M.J. Recoupling the cardiac nitric oxide synthases: Tetrahydrobiopterin synthesis and recycling. *Curr. Heart Fail. Rep.* 2012, 9(3): 200–210.
- American Diabetes Association, Classification and Diagnosis of Diabetes. *Diabetes Care*, 2015, 38 (Suppl 1): S8–S16.
- Angelovich, T.A., Shi, M.D.Y., Zhou, J., Maisa, A., Hearps, A.C., Jaworowski, A., 2016. Ex vivo foam cell formation is enhanced in monocytes from older individuals by both extrinsic and intrinsic mechanisms. *Exp. Gerontol.* 2016, 80: 17–26.
- Antunes, L.C., Elkfury, J.L., Jornada, M.N., Foletto, K.C., Bertoluci, M.C. Validation of HOMA-IR in a model of insulin-resistance induced by a high-fat diet in Wistar rats. *Arch. Endocrinol. Metab.* 2016, 60 (2): 138–142.
- Animal Resources Centre, 2016. Rat and Mice Weights. *Anim. Resour. Cent.*, (Online), (http://www.arc.wa.gov.au/?page_id=125, diakses 12 November 2016).
- Avwiuro, G. Histochemical Uses of Hematoxylin. *Journal of Pharmacology and Clinical Science.*, 2011, 1 (5): 24–34.
- Badan Penelitian dan Pengembangan Kesehatan, 2013. *Riset Kesehatan Dasar (RISKESDAS) 2013*. Epi Info., Kemenkes RI, Jakarta, hal.83-87.
- Baranska, M. 2014. *Optical Spectroscopy and Computational Methods in Biology and Medicine*, 14th Ed., Springer, New York, p. 510-512.
- Buettner, R., Parhofer, K.G., Woenckhaus, M., Wrede, C.E., Kunz-Schughart, L, Schölmerich, J., Bollheimer, L.C. Defining High-Fat-Diet Rat Models: Metabolic and Molecular Effects of Different Fat Types. *J. Mol. Endocrinol.*, 2006, 36 (3): 485–501.

- Burns, C., Morris, T., Jones, B., Koch, W., Borer, M., Riber, U., Bristow, A.. EXPERT Committee on Biological Standardization; Expert Committee on Specification For Pharmaceutical Preparation. *World Health Organ. Tech. Rep. Ser.*,2010, 96: 1–19.
- Cacho, J., Sevillano, J., de Castro, J., Herrera, E., Ramos, M.P. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. *Am. J. Physiol. Endocrinol. Metab.*,2008, 295 (5): E1269–76.
- Chhabra, N. Endothelial dysfunction – A predictor of atherosclerosis. *Internet J Med Update*. 2009, 4 (1): 33–41.
- Chikezie, PC., Ojiako, OA., Ogbuji, AC., Oxidative Stress in Diabetes Mellitus. *Integrative Obesity in Diabetes Mellitus*, 2015, 1(3): 71-79.
- Chogtu, B., Magazine, R., Bairy, K.L. Statin Use and Risk of Diabetes Mellitus. *World J. Diabetes*, 2015, 6 (2): 352–7.
- Dave, M., Nash, M., Young, G.C., Ellens, H., Magee, M.H., Roberts, A.D., Taylor, M., Greenhill, R.W., Boyle, G.W. Disposition and Metabolism of Darapladib, a Lipoprotein-associated Phospholipase A₂ inhibitor in Humans. *Drug Metab. Dispos*, 2014, 42 (3): 415–430.
- Davidson, E.P., Coppey, L.J., Calcutt, N.A., Oltman, C.L., Yorek, M.A. Diet Induced Obesity in Sprague Dawley Rats Causes Microvascular and Neural Dysfunction. *Diabetes. Metab. Res. Rev*, 2011, 26 (4): 306–318.
- DeFronzo, R.A. Insulin Resistance, Lipotoxicity, Type 2 Diabetes and Atherosclerosis: The Missing Links. The Claude Bernard Lecture 2009. *Diabetologia*, 2010, 53 (7): 1270–1287.
- Douglas, G., Channon, K.M. The Pathogenesis of Atherosclerosis. *Medicine*, 2014, 42 (9): 480–484.
- Draznin, B. Molecular Mechanisms of Insulin Resistance: Serine Phosphorylation of Insulin Receptor Substrate-1 and Increased Expression of p85 α : The Two Sides of a Coin. *Diabetes*, 2006, 55 (8): 2392–2397.
- Fajans, S.S., Bell, G.I. MODY: History, Genetics, Pathophysiology, And Clinical Decision Making. *Diabetes Care*, 2011, 34 (8): 1878–1884.
- Falk, E., Pathogenesis of Atherosclerosis. *J. Am. Coll. Cardiol*, 2006, 47 (8): C7-12.
- Favero, G., Paganelli, C., Buffoli, B., Rodella, L.F., Rezzani, R. Endothelium And Its Alterations In Cardiovascular Diseases: Life Style Intervention. *Biomed Res. Int*, 2014, 2014: 28

- Féry, F., Paquot, N. Etiopathogenesis And Pathophysiology Of Type 2 Diabetes. *Rev. Med. Liege*, 2010, 60 (6): 361–368.
- Fetita, L.-S., Sobngwi, E., Serradas, P., Calvo, F., Gautier, J.-F. Consequences Of Fetal Exposure To Maternal Diabetes In Offspring. *J. Clin. Endocrinol. Metab*, 2006, 91 (10): 3718–24.
- Fok, P.-W. Growth Of Necrotic Cores In Atherosclerotic Plaque. *Math. Med. Biol*, 2012, 29 (4): 301–27.
- Fowler, M.J. Microvascular And Macrovascular Complications Of Diabetes. *Clin. Diabetes*, 2008, 26 (2): 77–82.
- Gajda, A., 2008. High Fat Diets For Diet-Induced Obesity Models. *Open Source Diets*. (Oktober), 2008–2010.
- Getz, G.S., Reardon, C. Diet And Murine Atherosclerosis. *Arterioscler. Thromb. Vasc. Biol*, 2006, 26 (2): 242–249.
- Ghosh, SS., Righi, S., Krieg, R., Kang, L., Carl, D., Wang, J., Massey, HD., Gehr, TW., Ghosh, S., High Fat High Cholesterol Diet (Western Diet) Aggravates Atherosclerosis, Hyperglycemia and Renal Failure in Nephrectomized LDL Receptor Knockout Mice: Role of Intestine Derived Lipopolysaccharide. *PLoS One*, 2015, 10(11): e0141109.
- Giacco, F., Brownlee, M. Oxidative Stress And Diabetic Complications. *Circ. Res*, 2010, 107 (9): 1058–1070.
- Gonçalves, I., Edsfeldt, A., Ko, N.Y., Grufman, H., Berg, K., Björkbacka, H., Nitulescu, M., Persson, A., Nilsson, M., Prehn, C., Adamski, J., Nilsson, J. Evidence Supporting A Key Role Of Lp-PLA2-Generated Lysophosphatidylcholine In Human Atherosclerotic Plaque Inflammation. *Arterioscler. Thromb. Vasc. Biol*, 2012, 32 (6): 1505–1512.
- Graham, I.M. Risk Factors & Cardiovascular Disease. *Dialogues Cardiovasc. Med*. 2008. 13 (2): 77–152.
- Graham, M.L., Janecek, J.L., Kittredge, J.A., Hering, B.J., Schuurman, H.J. The Streptozotocin-Induced Diabetic Nude Mouse Model: Differences Between Animals From Different Sources. *Comp. Med*, 2011, 61 (4): 356–360.
- Heinecke, J.W. The Not-So-Simple HDL Story: A New Era For Quantifying HDL And Cardiovascular Risk?. *Nat. Med*, 2012, 18 (9): 1346–7.
- Heriansyah, T., Wihastuti, T., Anita, K., Iskandar, A., Suhendra, R., Setiabudi, P., Sishartami, L. Atherogenesis Inhibition By Darapladib Administration In Dyslipidemia Model Sprague-Dawley Rats. *Natl. J. Physiol. Pharm Pharmacol.*, 2016, 6 (1): 1–7.

- Holt, R.I.G., Cockram, C.S., Flyvbjerg, A., Goldstein, B.J., 2010. *Textbook of Diabetes: Fourth Edition*, 4th Ed., Blackwell Scientific Publication, Cambridge, p. 68-69 .
- Hong, Young Mi. Atherosclerotic Cardiovascular Disease Beginning in Childhood. *Korean Circ Journal*, 2010, 40(1):1-9.
- Hu, C., Tompson, D., Magee, M., Chen, Q., Liu, Y.M., Zhu, W., Zhao, H., Gross, A.S., Liu, Y. Single And Multiple Dose Pharmacokinetics , Pharmacodynamics And Safety Of The Novel Lipoprotein-Associated Phospholipase A₂Enzyme Inhibitor Darapladib In Healthy Chinese Subjects : An Open Label Phase-1 Clinical Trial. *PLoS One*, 2015, 10 (10): 1–15.
- Immanuel, S., Tjiptaningrum, A. Lipoprotein-Associated Phospholipase A₂ (Lp-PLA₂) Sebagai Petanda Penyakit Jantung Koroner. *Maj Kedokt Indon*, 2010, 60 (1): 32–39.
- Johnson, J.L., Shi, Y., Snipes, R., Janmohamed, S., Rolfe, T.E., Davis, B., Postle, A., Macphee, C.H. Effect Of Darapladib Treatment On Endarterectomy Carotid Plaque Lipoprotein-Associated Phospholipase A₂Activity: A Randomized, Controlled Trial. *PLoS One*, 2014, 9 (2): e89034.
- Kaplan, M., Aviram, M., Hayek, T. Oxidative Stress And Macrophage Foam Cell Formation During Diabetes Mellitus-Induced Atherogenesis: Role Of Insulin Therapy. *Pharmacol. Ther*, 2012, 136 (2): 175-185.
- Karakas, M., Koenig, W. Lp-Pla₂ Inhibition-The Atherosclerosis Panacea?. *Pharmaceuticals*, 2010, 3: 1360–1373.
- Knol, M.J., Twisk, J.W.R., Beekman, T.F., Heine, R.J., Snoek, F.J., Pouwer, F. Depression As A Risk Factor For The Onset Of Type 2 Diabetes Mellitus. A Meta-Analysis. *Diabetologia*, 2006, 49 (5): 837–845.
- Kolluru, G.K., Bir, S.C., Kevil, C.G. Endothelial Dysfunction And Diabetes: Effects On Angiogenesis, Vascular Remodeling, And Wound Healing. *Int. J. Vasc. Med*, 2012, 2012: 1–30.
- Koolhas, J.M., 2010. *The Laboratory Rat*, in: Hubrecht, R., Kirkwood, J. (Eds.), *The UFAW Handbook On The Care And Management Of Laboratory And Other Research Animals*. Wiley-Blackwell, Cambridge, p. 311–326.
- Krinke, GJ., 2000. *The Laboratory Rat*. Elsevier, 1st Ed., Academic Press, New York, p. 447.
- Kučera, O., Garnol, T., Lotková, H., Staňková, P., Mazurová, Y., Hroch, M., Bolehovská, R., Roušar, T., Červinková, Z. The Effect Of Rat Strain, Diet Composition And Feeding Period On The Development Of A Nutritional

Model Of Non-Alcoholic Fatty Liver Disease In Rats. *Physiol. Res*, 2011, 27 (25): 261–265.

Kumar, V., Cotran, R., Robbins, S.L., 2007. *Robbin's Basic Pathology*, 8thEd., Elsevier Inc., New York, p. 767-769.

Lacolley, P., Regnault, V., Nicoletti, A., Li, Z., Michel, J.B. The Vascular Smooth Muscle Cell In Arterial Pathology: A Cell That Can Take On Multiple Roles. *Cardiovasc. Res*, 2012, 95 (2): 194-204.

Lee, H.Y., Oh, E., Kim, S.D., Seo, J.K., Bae, Y.S. Oxidized Low-Density Lipoprotein-Induced Foam Cell Formation Is Mediated By Formyl Peptide Receptor 2. *Biochem. Biophys. Res. Commun*, 2014, 443 (3): 1003–1007.

Lee YS, Li P, Huh JY, Hwang IJ, Lu M, Kim JI, *et al.* Inflammation is Necessary For Long-term But Not Short-term High-fat Diet-induced Insulin Resistance. *Diabetes*. 2011.60(10):2474–83.

Liemburg-Apers, D.C., Willems, P.H.G.M., Koopman, W.J.H., Grefte, S. Interactions Between Mitochondrial Reactive Oxygen Species And Cellular Glucose Metabolism. *Arch. Toxicol*, 2015, 89 (8): 1209–1226.

Lohoefer, F., Reeps, C., Lipp, C., Rudelius, M., Zimmermann, A., Ockert, S., Eckstein, HH., Pelisek, J. Histopathological Analysis of Cellular Localization of Cathepsins in Abdominal Aortic Aneurysm Wall. *International Journal of Experimental Pathology*, 2012, 93:252-8.

Longo, D.L., Fauci, A.S., Kasper, D.L., Hauser, S.L., Jameson, J.L., Loscalco, J., 2015. *Harrison's Principles Of Internal Medicine*, 19th Ed., McGraw-Hill Education, New York, p. 486-488.

Louis, S.F., Zahradka, P. Vascular Smooth Muscle Cell Motility: From Migration To Invasion. *Exp. Clin. Cardiol*, 2010, 15 (4): e75–e85.

MacDougall, ED., Kramer, Farah., Polinsky, Patti., Barnhart, Shelley., Askari, Bardia., Johansson, Fredrik., Varon, Rebecca., Rosenfeld, ME., *et al.* Aggressive Very Low-Density Lipoprotein (VLDL) and LDL Lowering by Gene Transfer of the VLDL Receptor Comined With A Low-Fat Diet Regimen Induces Regression and Reduces Macrophage Content in Advanced Atherosclerotic Lesions in LDL Receptor-Deficient Mice. *Vascular Biology*, 2006, 168(6):2064-73.

Manolakou, P., Angelopoulou, R., Bakoyiannis, C., Psathas, E., Bastounis, E., Kavantzias, N., Patsouris, E. Cellular Proliferation In Complicated Versus Uncomplicated Atherosclerotic Lesions: Total Cell Population, Foam Cells And Newly Formed Microvessels. *Tissue Cell*, 2009, 41 (6): 408–413.

- Marso, S.P., Stern, D.M. 2004. *Diabetes And Cardiovascular Disease*, 1st Ed., Lippincott Williams & Wilkins, Philadelphia. P 507-510.
- Mohler, ER., Ballantyne, CM., Davidson, MH., Hanefeld, M., Johnson, JL., Zalewski, A. The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients with Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. *J Am Coll Cardiol*, 2008, 51(17): 1632-41.
- Murwani, S., Ali, M., Muliarta, K. Diet Aterogenik Pada Tikus Putih (*Rattus norvegicus* strain Wistar) Sebagai Model Hewan Atherosklerosis. *J. Kedokt. Brawijaya*, 2006, 22 (1): 6–9.
- Nakaya H, Summers BD, Nicholson AC, Gotto AM, Hajjar DP, Han J. Atherosclerosis in LDLR-Knockout Mice Is Inhibited, but Not Reversed, by the PPAR γ Ligand Pioglitazone. *Am J Pathol*, 2009, 174(6): 2007-14.
- Neuhofer, A., Wernly, B., Leitner, L., Sarabi, A., Sommer, NG., Staffler, G., Zeyda, M., Stulnig, TM. An Accelerated Mouse Model for Atherosclerosis and Adipose Tissue Inflammation. *Cardiovascular Diabetology*, 2014, 13:23.
- Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: A tale of Eva and ADAM in Cardiovascular Risk Assessment and Prevention. *Hypertension*, 2009, 54:3–10.
- Ning B, Wang X, Yu Y, Waqar AB, Yu Q, Koike T, *et al*. High-fructose and High-fat diet-induced Insulin Resistance Enhances Atherosclerosis in Watanabe Heritable Hyperlipidemic Rabbits. *Nutr Metab*. 2015.12(1):1-11.
- Nowacek, J.M., 2010. *Fixation and Tissue Processing*, in: *Special Stains and H & E*, Dako, California, p. 141–152.
- Okamoto, T., Kanemoto, N., Ohbuchi, Y., Okano, M., Fukui, H., Sudo, T. Characterization of STZ-Induced Type 2 Diabetes in Zucker Fatty Rats. *Exp. Anim*, 2008, 57 (4): 335–345.
- Ozougwu, J., Obimba, K., Belonwu, C., Unakalamba, C. The Pathogenesis And Pathophysiology Of Type 1 And Type 2 Diabetes Mellitus. *J. Physiol. Pathophysiol*, 2013, 4 (4): 46–57.
- PERKENI. 2011. *Konsensus Pengelolaan Dan Pencegahan Diabetes Mellitus Tipe 2 Di Indonesia*. PERKENI, Jakarta, hal. 14-20.
- Rafieian-Kopaei, M., Setorki, M., Doudi, M., Baradaran, A., Nasri, H. Atherosclerosis: Process, Indicators, Risk Factors And New Hopes. *Int. J. Prev. Med*, 2014, 5 (8): 927-946.

- Ridwan, E. Etika Pemanfaatan Hewan Percobaan dalam Penelitian Kesehatan. *J. Indones. Med. Assos*, 2013, 63 (3): 112–116.
- Riley, R.F., Corson, M.A. Darapladib, A Reversible Lipoprotein-Associated Phospholipase A2 Inhibitor, For The Oral Treatment Of Atherosclerosis And Coronary Artery Disease. *IDrugs*, 2009, 12 (10): 648–55.
- Rolls, G., 2011. An Introduction to Specimen Preparation. (Online) (<http://www.leica-biosystems.com/pathologyleaders/an-introduction-to-specimen-preparation/>, diakses 10 September 2016).
- Rosenson, R.S., Hurt-Camejo, E. Phospholipase A₂Enzymes And The Risk Of Atherosclerosis. *Eur. Heart J*, 2012, 33 (23): 2899–2909.
- Rudijanto, A. The Role Of Vascular Smooth Muscle Cells On The Pathogenesis Of Atherosclerosis. *Acta Med. Indones*, 2007, 39 (2): 86–93.
- Rupp, H., Bernhard, M., 2012. *Control Of Gene Expression By Catecholamines And The Renin-Angiotensin System*, Springer Science & Business Media, New York, p. 239-243.
- Sakellarios, A.I., Siogkas, P., Exarchos, T., Stefanou, K., Bourantas, C.V. Modelling LDL Accumulation In The Case Of Endothelial Dysfunction. *J. Serbian Soc. Comput. Mech*, 2011, 5 (2): 90–100.
- Sena, C.M., Pereira, A.M., Seica, R. Endothelial Dysfunction - A Major Mediator Of Diabetic Vascular Disease. *Biochim. Biophys. Acta*, 2013, 1832 (12): 2216–2231.
- Sengupta, P. The Laboratory Rat: Relating Its Age With Human's. *Int. J. Prev. Med*, 2013, 4 (6): 624-630.
- Serruys, P.W., García-García, H.M., Buszman, P., Erme, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, O., Dudek, D., Bøtker, H.E., Von Birgelen, C., D'Amico, D., Hutchinson, T., Zambanini, A., Mastik, F., Van Es, G.A., Van Der Steen, A.F.W., Vince, D.G., Ganz, P., Hamm, C.W., Wijns, W., Zalewski, A. Effects Of The Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib On Human Coronary Atherosclerotic Plaque. *Circulation*, 2008, 118 (11): 1172–1182.
- Sharma, A., Sellers, S., Stefanovic, N., Leung, C., Tan, S.M., Huet, O., Granville, D.J., Cooper, M.E., de Haan, J.B., Bernatchez, P. Direct Endothelial Nitric Oxide Synthase Activation Provides Atheroprotection In Diabetes-Accelerated Atherosclerosis. *Diabetes*, 2015, 64 (11): 3937–3950.
- Shaw, J.E., Sicree, R.A., Zimmet, P.Z. Global Estimates Of The Prevalence Of Diabetes For 2010 And 2030. *Diabetes Res. Clin. Pract*, 2013, 87 (1): 4–14.

- Simionescu, M., Sima, A. V., 2012. *Morphology Of Atherosclerotic Lesions. Inflammation And Atherosclerosis*. p. 19–38.
- Spagnoli, L.G., Bonanno, E., Sangiorgi, G., Mauriello, A. Role Of Inflammation In Atherosclerosis. *J. Nucl. Med*, 2007, 48 (11): 1800–1815.
- Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C.L., Ramarao, P. Combination Of High-Fat Diet-Fed And Low-Dose Streptozotocin-Treated Rat: A Model For Type 2 Diabetes And Pharmacological Screening. *Pharmacol. Res*, 2005, 52 (4): 313–320.
- Tselepis, AD., Rizzo, M., Goudevenos, IA. Therapeutic Modulation of Lipoprotein-associated Phospholipase A₂ (Lp-PLA₂). *Current Pharmaceutical Design*, 2011, 17: 3656-61.
- Van Dijk, T.H., Laskewitz, a J., Grefhorst, A., Boer, T.S., Bloks, V.W., Kuipers, F., Groen, a K., Reijngoud, D.J. A Novel Approach To Monitor Glucose Metabolism Using Stable Isotopically Labelled Glucose In Longitudinal Studies In Mice. *Lab. Anim*, 2013, 47 (2): 79–88.
- Wang, D., Zhuang, Y., Tian, Y., Thomas, G.N., Ying, M., Tomlinson, B. Study of the effects of total flavonoids of Astragalus on atherosclerosis Formation And Potential Mechanisms. *Oxid Med Cell Longev*, 2012, 2012: 28-38.
- Wang, M., Monticone, R.E., Lakatta, E.G. Arterial Aging: A Journey Into Subclinical Arterial Disease. *Curr. Opin. Nephrol. Hypertens*, 2010, 19 (2): 201–7.
- Wang, T., Law, K., Yanagawa, B., Yam, J., Butany, J. Atherosclerosis: Pathogenesis And Pathology. *Diagnostic Histopathol*, 2012, 18 (11): 461–467.
- Wang, W., Zhang, J., Wu, W., Li, J., Ma, Y., Chen, W., Yan, H., Wang, K., Xu, W., Shen, J., Wang, Y. Inhibition Of Lipoprotein-Associated Phospholipase A₂ Ameliorates Inflammation And Decreases Atherosclerotic Plaque Formation In Apoe-Deficient Mice. *PLoS One*, 2011, 6 (8): e23425.
- White, H., Held, C., Stewart, R., Watson, D., Harrington, R., Budaj, A., Steg, P.G., Cannon, C.P., Krug-Gourley, S., Wittes, J., Trivedi, T., Tarka, E., Wallentin, L. Study Design And Rationale For The Clinical Outcomes Of The STABILITY Trial (Stabilization Of Atherosclerotic Plaque By Initiation Of Darapladib Therapy) Comparing Darapladib Versus Placebo In Patients With Coronary Heart Disease. *Am. Heart J*, 2010, 160 (4): 655–661.
- White, H., Held, C., Stewart, R., Watson, D., Harrington, R., Budaj, A., Steg, P.G., Cannon, C.P., Wallentin, L. Darapladib For Preventing Ischemic

Events In Stable Coronary Heart Disease. *N. Engl. J. Med*, 2014, 370 (18): 1702–1711.

WHO, 2014. *Diabetes*, (Online),

(<http://www.who.int/mediacentre/factsheets/fs312/en/>), diakses 27 Oktober 2015).

WHO, 2012. *Cardiovascular Diseases (CVDs)*, (Online),

(<http://www.who.int/mediacentre/factsheets/fs317/en/>), diakses 28 Oktober 2016)

Wihastuti, T.A., Widodo, M.A., Heriansyah, T., Apramadha, N., Sari, K. Study Of The Inhibition Effect Of Ethanolic Extract Of Mangosteen Pericarp On Atherogenesis In Hypercholesterolemic Rat. *Asian Pacific J. Trop. Dis*, 2015, 5 (10): 830–834.

Wilensky, R.L., Shi, Y., Iii, E.R.M., Hamamdzic, D., Burgert, M.E., Postle, A., Fenning, R.S., Bollinger, J.G., Hoffman, B.E., Daniel, J., Yang, J., Mirabile, R.C., Webb, C.L., Zhang, L., Zhang, P., Gelb, M.H., Walker, M.C., Zalewski, A., Macphee, C.H. Inhibition Of Lipoprotein-Associated Phospholipase A2 Reduces Complex Coronary Atherosclerotic Plaque Development. *Nat. Med*, 2010, 14 (10): 1059–1066.

Wong, B.W., Meredith, A., Lin, D., McManus, B.M. The Biological Role Of Inflammation In Atherosclerosis. *Can. J. Cardiol*, 2012, 28 (6): 631–641.

Wu, K.K., Huan, Y. Diabetic Atherosclerosis Mouse Models. *Atherosclerosis*, 2007, 191 (2): 241–249.

Xiang, X., Wang, Z., Zhu, Y., Bian, L., Yang, Y. Dosage Of Streptozocin In Inducing Rat Model Of Type 2 Diabetes Mellitus. *Wei Sheng Yan Jiu*, 2010, 39 (2): 138–142.

Xu, Zheng-Jie., Fan, Jian-Gao., Ding, Xiao-Dong., Qiao, Liang., Wang, Guo-Liang. Characterization of High-Fat, Diet Induced, Non-Alcoholic Steatohepatitis with Fibrosis in Rats. *Dig Dis Sci*, 2010, 55: 931-40.

Yu, X.-H., Fu, Y.-C., Zhang, D.-W., Yin, K., Tang, C.-K. Foam Cells In Atherosclerosis. *Clin. Chim. Acta*, 2013, 424: 245–52.

Zhang, J., Xu, D., Liu, X., Bi, S., Zhao, T., Sui, S., Ji, X., Lu, Q. Darapladib , A Lipoprotein-Associated Phospholipase A2 Inhibitor , Reduces Rho Kinase Activity In Atherosclerosis. *Yonsei Med. J*, 2016, 57 (2): 321–327.

Zhang, M., Lv, X.-Y., Li, J., Xu, Z.-G., Chen, L. The Characterization Of High-Fat Diet And Multiple Low-Dose Streptozotocin Induced Type 2 Diabetes Rat Model. *Exp. Diabetes Res*, 2008: 1–9.

Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hiraoka, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., Cooper, M.E., Glasziou, P.,

Grobbee, D., Hamet, P., Harrap, S., Heller, S., Lisheng, L., Mancia, G., Marre, M., Matthews, D.R., Mogensen, C.E., Perkovic, V., Poulter, N., Rodgers, A., Williams, B., MacMahon, S., Patel, A., Woodward, M. Follow-Up Of Blood-Pressure Lowering And Glucose Control In Type 2 Diabetes. *N. Engl. J. Med*, 2014, 371 (15): 1392–1406.

